|
Press Releases |
|
|
|
Wednesday, September 6, 2017 |
|
雅各臣發行5億港元可換股票據予Dragons 615 Limited及HH InRe JP, Ltd. |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)建議按一般授權發行二零二零年到期、本金總額5億港元的可換股票據予兩名認購人,分別為Dragons 615 Limited (「Dragons」,DCP China Credit Fund I, L.P. (「DCP Fund」)之全資擁有的有限公司)及HH InRe JP, Ltd. (「HH JP」,一間由Hillhouse InRe Fund, L.P.間接全資擁有的有限公司)。 more info >> |
|
Jacobson Pharma Issues HK$500M of Convertible Notes to Dragons 615 and HH InRe JP, Ltd. |
Jacobson Pharma Corporation Limited , a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has proposed to issue Convertible Notes under general mandate, in an aggregate principal amount of HK$500 million due in 2020, to two subscribers namely Dragons 615 Limited and HH InRe JP, Ltd. more info >> |
|
Sunday, June 25, 2017 |
|
雅各臣公布二零一七年全年业绩 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「公司」;股份代号:2633)今天公布公司及附属公司(统称「集团」)截至二零一七年三月三十一日止年度(「二零一七财年」)的全年业绩,亦是公司在去年九月于香港上市后的首份全年业绩。 more info >> |
|
雅各臣公佈二零一七年全年業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「公司」;股份代號:2633)今天公佈公司及附屬公司(統稱「集團」)截至二零一七年三月三十一日止年度(「二零一七財年」)的全年業績,亦是公司在去年九月於香港上市後的首份全年業績。 more info >> |
|
Jacobson Pharma Announces 2017 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2017 ( "FY 2017" ). more info >> |
|
Wednesday, April 26, 2017 |
|
香港李众胜堂保济丸与「水滴无界」签订合作协议 |
李众胜堂(集团)有限公司(「李众胜堂」或「公司」)今天出席「水滴无界」于北京的上线启动仪式,并由代表与「水滴无界」签订合作协议,正式标志着双方展开于中国大陆市场携手合作的新里程。 more info >> |
|
香港李眾勝堂保濟丸與「水滴無界」簽訂合作協議 |
李眾勝堂(集團)有限公司(「李眾勝堂」或「公司」)今天出席「水滴無界」於北京的上線啟動儀式,並由代表與「水滴無界」簽訂合作協議,正式標誌著雙方展開於中國大陸市場攜手合作的新里程。 more info >> |
|
Monday, March 13, 2017 |
|
雅各臣公布收购康宁行70%权益 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业-雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布收购康宁行集团(包括「康宁行有限公司」及其香港附属公司)的70%权益,总代价为56,000,000港元。 more info >> |
|
雅各臣公布收購康寧行70%權益 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業-雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈收購康寧行集團(包括「康寧行有限公司」及其香港附屬公司)的70%權益,總代價為56,000,000港元。完成收購後,康寧行集團將成為雅各臣間接非全資附屬公司。 more info >> |
|
Jacobson Pharma Announces Acquisition of 70% Interest in Hong Ning Hong |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
TANAKA 홀딩스, 본사를 창업지 카야바초 새로운 본사 빌딩으로 이전
Mar 19, 2024 10:00 HKT/SGT
|
|
|
Raychem RPG achieves significant milestone to facilitate faster execution in electricity distribution projects with its 'Make India' initiative
Mar 19, 2024 09:00 HKT/SGT
|
|
|
Seyond to Expand LiDAR Solutions for Autonomous Vehicles with NVIDIA DriveWorks and Omniverse Integration
Mar 19, 2024 08:00: JST
|
|
|
Seyond to Expand LiDAR Solutions for Autonomous Vehicles with NVIDIA DriveWorks and Omniverse Integration
Mar 19, 2024 07:00 HKT/SGT
|
|
|
亿胜生物公布2023年度业绩,收入增长29.5%,利润增长22.1%
Mar 18, 2024 21:32 HKT/SGT
|
|
|
億勝生物公布2023年度業績,收入增長29.5%,利潤增長22.1%
Mar 18, 2024 21:31 HKT/SGT
|
|
|
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
Mar 18, 2024 21:30 HKT/SGT
|
|
|
Breaking Boundaries: Dubai Set to Redefine Blockchain Technology at WBS Dubai
Mar 18, 2024 19:04: JST
|
|
|
Breaking Boundaries: Dubai Set to Redefine Blockchain Technology at WBS Dubai
Mar 18, 2024 18:04 HKT/SGT
|
|
|
三菱重工、役員人事を発表
Mar 18, 2024 18:00: JST
|
|
|
男裝龍頭中國利郎:2023年淨利增長18.4% 輕商務系列大幅增長35.2% 新零售漸露頭角
Mar 18, 2024 17:36 HKT/SGT
|
|
|
男装龙头中国利郎:2023年净利增长18.4% 轻商务系列大幅增长35.2% 新零售渐露头角
Mar 18, 2024 17:35 HKT/SGT
|
|
|
Nissan and Mitsubishi Corporation agree to explore new business in next-generation-mobility and energy-related services utilizing EVs
Mar 18, 2024 17:29 JST
|
|
|
云顶新耀:创新药企低谷中的增长秘诀
Mar 18, 2024 16:23 HKT/SGT
|
|
|
雲頂新耀:創新藥企低谷中的增長秘訣
Mar 18, 2024 16:22 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|